Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON38355Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone acetate plus prednisone with Placebo plus prednisone (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Started Sep 2009; status: recruiting.
02
Drugs
abirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON38355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38355.